Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report

Abstract Background The symptoms of coronavirus disease 2019, caused by the novel severe acute respiratory syndrome coronavirus 2, were originally assumed to be mainly respiratory. With increasing knowledge, however, it turned out that the spectrum of complaints varies broadly with age and concomita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. Saleh, R. Jung, S. Tonner, F. Hornof, M. Strittmatter
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	COVID-19 Neuropathy Post-COVID-19 syndrome Case report Medicine R
Acceso en línea:	https://doaj.org/article/b8711d98b0464b60a568f00560069075
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b8711d98b0464b60a568f00560069075
record_format	dspace
spelling	oai:doaj.org-article:b8711d98b0464b60a568f005600690752021-11-08T11:13:54ZPost-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report10.1186/s13256-021-03148-y1752-1947https://doaj.org/article/b8711d98b0464b60a568f005600690752021-11-01T00:00:00Zhttps://doi.org/10.1186/s13256-021-03148-yhttps://doaj.org/toc/1752-1947Abstract Background The symptoms of coronavirus disease 2019, caused by the novel severe acute respiratory syndrome coronavirus 2, were originally assumed to be mainly respiratory. With increasing knowledge, however, it turned out that the spectrum of complaints varies broadly with age and concomitant diseases. While many neurological symptoms were reported in the context of the disease, ranging from permanent fatigue to recurrent headaches and concentration disturbance, treatment approaches are still in development. This case discusses a possible treatment approach with immunoglobulin therapy and its outcomes. Case presentation We present the case of a 56-year-old Caucasian female patient who, following coronavirus disease 2019, developed peripheral sensory and autonomic disturbances that fell within subacute demyelinating neuropathy. Because a significant improvement in symptoms as well as in the results of clinical and electrophysiological examination was reported after immunoglobulin therapy, long-term therapy does not appear to be necessary. Conclusion Given the significant subjective and objective improvement reported, this case provides additional evidence that immunoglobulin therapy can be considered in post-coronavirus disease 2019 syndrome.A. SalehR. JungS. TonnerF. HornofM. StrittmatterBMCarticleCOVID-19NeuropathyPost-COVID-19 syndromeCase reportMedicineRENJournal of Medical Case Reports, Vol 15, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 Neuropathy Post-COVID-19 syndrome Case report Medicine R
spellingShingle	COVID-19 Neuropathy Post-COVID-19 syndrome Case report Medicine R A. Saleh R. Jung S. Tonner F. Hornof M. Strittmatter Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
description	Abstract Background The symptoms of coronavirus disease 2019, caused by the novel severe acute respiratory syndrome coronavirus 2, were originally assumed to be mainly respiratory. With increasing knowledge, however, it turned out that the spectrum of complaints varies broadly with age and concomitant diseases. While many neurological symptoms were reported in the context of the disease, ranging from permanent fatigue to recurrent headaches and concentration disturbance, treatment approaches are still in development. This case discusses a possible treatment approach with immunoglobulin therapy and its outcomes. Case presentation We present the case of a 56-year-old Caucasian female patient who, following coronavirus disease 2019, developed peripheral sensory and autonomic disturbances that fell within subacute demyelinating neuropathy. Because a significant improvement in symptoms as well as in the results of clinical and electrophysiological examination was reported after immunoglobulin therapy, long-term therapy does not appear to be necessary. Conclusion Given the significant subjective and objective improvement reported, this case provides additional evidence that immunoglobulin therapy can be considered in post-coronavirus disease 2019 syndrome.
format	article
author	A. Saleh R. Jung S. Tonner F. Hornof M. Strittmatter
author_facet	A. Saleh R. Jung S. Tonner F. Hornof M. Strittmatter
author_sort	A. Saleh
title	Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
title_short	Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
title_full	Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
title_fullStr	Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
title_full_unstemmed	Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
title_sort	post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report
publisher	BMC
publishDate	2021
url	https://doaj.org/article/b8711d98b0464b60a568f00560069075
work_keys_str_mv	AT asaleh postcoronavirusdisease2019polyneuropathywithsignificantresponsetoimmunoglobulintherapyacasereport AT rjung postcoronavirusdisease2019polyneuropathywithsignificantresponsetoimmunoglobulintherapyacasereport AT stonner postcoronavirusdisease2019polyneuropathywithsignificantresponsetoimmunoglobulintherapyacasereport AT fhornof postcoronavirusdisease2019polyneuropathywithsignificantresponsetoimmunoglobulintherapyacasereport AT mstrittmatter postcoronavirusdisease2019polyneuropathywithsignificantresponsetoimmunoglobulintherapyacasereport
_version_	1718442367828099072

Post-coronavirus disease 2019 polyneuropathy with significant response to immunoglobulin therapy: a case report

Ejemplares similares